Epigenetic and MicroRNA Biomarkers 2013 Market Report
This market report from SELECTBIO represents the most up-to-date analysis of the Epigenetic and MicroRNA Biomarkers spaces together with research market data [qualitative and quantitative analysis] characterizing the epigenetics and microRNA research fields
CHAPTER I. EPIGENETICS RESEARCH MARKET ANALYSIS
Primary Market Survey to Characterize Marketplace from the Bottom-Up: Qualitative and Quantitative Market Data
Current Research Paradigms
Quantitative Segmentation of Epigenetics Research
Epigenetics Research in Cancer: Quantitative Segmentation
Commercial Kit and Reagent Offerings in the Epigenetics Research Marketplace
CHAPTER II. EPIGENETIC SIGNATURES AS POTENTIAL BIOMARKERS
Big Data Analysis of Epigenetics Publication Landscape
Hotspot Analysis of Publications Describes Segments of Opportunity vis-à-vis Research Product Development as well as Potential Assay Development for Disease Associations, Harvesting of Prognostic as well as Diagnostic Biomarkers
Epigenetic Signatures Described in Various Disease Classes
DNA Methylation as Disease Biomarkers
Histone Modifications as Disease Biomarkers
Potential Epigenetic Biomarkers in Various Cancer Classes
Gastric Cancer
Pancreatic Cancer
Prostate Cancer
CHAPTER III. MICRORNA RESEARCH MARKET ANALYSIS
microRNA Signatures as Potential Biomarkers
Primary Market Survey to Characterize Marketplace from the Bottom-Up: Qualitative and Quantitative Market Data
microRNA Research vis-à-vis Content Classes
microRNA Research in Cancer
microRNA Research Workflow: Quantitative Breakout
microRNA Expression Profiling Quantitative Market Breakout
microRNA Vendor Market Penetration Space Map
NGS to Study microRNAs—Market Breakout by Platform
Unmet Needs in the microRNA Research Space
microRNA Signatures Described in Various Disease Classes: Potential for Biomarker Development
Tumor Suppressor microRNA Methylation
microRNAs in Biofluids
Circulating microRNAs as Potential Tumor Markers
CHAPTER IV. CHARACTERIZATION OF MOLECULAR BIOMARKER CLASSES
Traditional Cancer Biomarkers
Oncogenes
Tumor Suppressor Genes
APPENDIX I. EPIGENETIC AND MICRORNA BIOMARKER SUMMARY
APPENDIX II. LIST OF COMPANION DIAGNOSTICS (CDX) ON THE MARKET, IN PROGRESS CDX IN DEVELOPMENT/PARTNERSHIPS, POTENTIAL MARKET SIZE FOR EPIGENETIC AND MICRORNA-BASED CDX
APPENDIX III. RESEARCH METHODOLOGY
Primary Market Survey to Characterize Marketplace from the Bottom-Up: Qualitative and Quantitative Market Data
Current Research Paradigms
Quantitative Segmentation of Epigenetics Research
Epigenetics Research in Cancer: Quantitative Segmentation
Commercial Kit and Reagent Offerings in the Epigenetics Research Marketplace
CHAPTER II. EPIGENETIC SIGNATURES AS POTENTIAL BIOMARKERS
Big Data Analysis of Epigenetics Publication Landscape
Hotspot Analysis of Publications Describes Segments of Opportunity vis-à-vis Research Product Development as well as Potential Assay Development for Disease Associations, Harvesting of Prognostic as well as Diagnostic Biomarkers
Epigenetic Signatures Described in Various Disease Classes
DNA Methylation as Disease Biomarkers
Histone Modifications as Disease Biomarkers
Potential Epigenetic Biomarkers in Various Cancer Classes
Gastric Cancer
Pancreatic Cancer
Prostate Cancer
CHAPTER III. MICRORNA RESEARCH MARKET ANALYSIS
microRNA Signatures as Potential Biomarkers
Primary Market Survey to Characterize Marketplace from the Bottom-Up: Qualitative and Quantitative Market Data
microRNA Research vis-à-vis Content Classes
microRNA Research in Cancer
microRNA Research Workflow: Quantitative Breakout
microRNA Expression Profiling Quantitative Market Breakout
microRNA Vendor Market Penetration Space Map
NGS to Study microRNAs—Market Breakout by Platform
Unmet Needs in the microRNA Research Space
microRNA Signatures Described in Various Disease Classes: Potential for Biomarker Development
Tumor Suppressor microRNA Methylation
microRNAs in Biofluids
Circulating microRNAs as Potential Tumor Markers
CHAPTER IV. CHARACTERIZATION OF MOLECULAR BIOMARKER CLASSES
Traditional Cancer Biomarkers
Oncogenes
Tumor Suppressor Genes
APPENDIX I. EPIGENETIC AND MICRORNA BIOMARKER SUMMARY
APPENDIX II. LIST OF COMPANION DIAGNOSTICS (CDX) ON THE MARKET, IN PROGRESS CDX IN DEVELOPMENT/PARTNERSHIPS, POTENTIAL MARKET SIZE FOR EPIGENETIC AND MICRORNA-BASED CDX
APPENDIX III. RESEARCH METHODOLOGY
This market report presents the current worldwide market landscape of epigenetic and microRNA
biomarkers. Presented herein are the following:
- Epigenetics Section Focuses on Characterized Biomarkers to Date, Publication Activity, DNAMethylation Biomarkers, Histone Modifications Characterized to Date, Kits and ReagentsCommercially-Available to Study Epigenetics. Primary Market Survey Data from Industry Participants[Researchers] Focusing on Epigenetics Provides Bottom-Up Insight into Epigenetics-Focused Researchand Practices
- MicroRNA Section Focuses on the Documented Associations of Specific microRNA Signatures withDiseases, especially Cancer. Presented herein are Publication Analysis of microRNA-focused Papersfrom the Scientific Literature, MicroRNAs as Circulating Biomarkers, the MicroRNA ResearchMarketplace Characterized via Primary Market Surveys where Data from Industry Participants[Researchers] Focusing on microRNAs Provides Bottom-Up Insight into Current MicroRNA Researchand Practices
Epigenetic Modifications May be Key Drivers in Oncology:Potential as Biomarkers to “Pinpoint” Driver Lesions:
- There are 28 million CpG located in the human genome in areas called “CpG islands”
- These CpG islands are normally in the un-methylated state [ie., in an “open chromatin”configuration allowing transcriptional activity to proceed through these regions]
- In tumors, however, CpG islands gain local methylation, however, there is a global lossof methylation genome-wide
- Epigenetic instability at the nuclear periphery appears to be pervasive in cancer
- Furthermore, there is “focal hypermethylation” which often occurs at stem cellpolycomb target loci—stem cell polycomb targets are prone to abnormal DNAmethylation in cancer
- Epigenetic Silencing of Tumor Suppressors and Other Loci Appears to be Critical in Cancer and therefore the Identification and Deployment of EpigeneticLesions in Cancer May Have Potential as Biomarkers for Prognostics,Diagnostics, and Personalized Medicine
